COMPANY OVERVIEW
InSphero, headquartered in Schlieren, Switzerland (Zurich area), pioneered scaffold-free 3D microtissue technology in 2009. Their 3D InSight platform creates highly reproducible spheroids for liver toxicity, metabolic disease, and oncology applications, with products deployed at 15 of the top 20 pharmaceutical companies worldwide.
3D INSIGHT PLATFORM
- Liver Microtissues: Primary hepatocyte + non-parenchymal cell co-cultures (Kupffer, stellate, endothelial)
- Islet Microtissues: Functional insulin-secreting beta cell models for diabetes
- Tumor Spheroids: Cancer cell line and primary tumor 3D models
- GravityPLUS: Hanging drop technology for uniform spheroid formation
- Akura Flow: Perfused multi-tissue system for ADME studies
KEY APPLICATIONS
- DILI prediction with long-term repeat-dose studies (28+ days)
- NASH/NAFLD disease modeling with steatosis, inflammation, and fibrosis
- Type 2 diabetes drug testing on functional islet models (GSIS assay)
- Tumor microenvironment for immuno-oncology compound screening
- CYP450 induction for drug-drug interaction assessment
REPRODUCIBILITY ADVANTAGE
InSphero's GravityPLUS technology produces spheroids with <10% size variation (CV), enabling quantitative assays and regulatory submissions. Their ready-to-use microtissue products ship overnight, eliminating in-house production variability that plagues many 3D cell culture approaches.